Table of Contents

• COVID-19 Vaccine and Bladder Cancer: Friend or Foe?

  Kevin Z. Qi, Miriam P. Palomino ... Yujiang Fang

  This is a letter to the editor on the discussion on COVID-19 vaccine and bladder cancer....

  EDITORIAL | Published: 31 Dec 2022

  Annals of Urologic Oncology, Volume 5 (2022), Issue 2

  Pages: 57-58   PDF(228KB)   Views：1201Downloads：3

• Novel Therapeutic Strategies for BCG-unresponsive Non-muscle Invasive Bladder Cancer

  Peng Zhang, Yi Ding

  Development of therapeutic strategies for non-muscle-invasive bladder cancer (NMIBC) that failed intravesical Bacillus Calmette - Guerin (BCG) therapy remains an urgent priority for clinicians. Currently, radical cystectomy is the recommended standard of care treatment options for these patients. Intravesical chemotherapy using gemcitabine and docetaxel are regarded as the most effective treatment...

  REVIEW | Published: 29 Nov 2022

  Annals of Urologic Oncology, Volume 5 (2022), Issue 2

  Pages: 59-67   PDF(1938KB)   Views：1081Downloads：7

• Targeting CTLA-4 in Cancer: Biological Insights with a Focus on Renal Cell Carcinoma

  Juan Wu, Ya-fei Ren ... Dong-sheng Li

  Renal cell carcinoma (RCC) is a complex group of malignant tumors characterized by immunosuppression and high invasiveness. In the majority of patients with advanced renal cell carcinoma, treatment fails to achieve a complete cure post-treatment. Efforts are needed to develop new therapeutics to improve the outcome of renal cell carcinoma. The "immune checkpoint" of T cells has attracted much atte...

  REVIEW | Published: 21 Dec 2022

  Annals of Urologic Oncology, Volume 5 (2022), Issue 2

  Pages: 68-74   PDF(1000KB)   Views：1139Downloads：7

• Research Progress on Ferroptosis as a Therapeutic Strategy in Renal Cell Carcinoma

  Minna Liu, Min Bai ... Peng Zhang

  Renal cell carcinoma (RCC) is a common type of kidney cancer in adults and constitutes approximately 90% of all renal malignancies. Although advancements have been made in the treatment of RCC, the 5 -year survival rate is still low, and new treatment modalities are still required. Ferroptosis is an iron-dependent programmed cell death caused by the accumulation of lipid peroxide products. Recent ...

  REVIEW | Published: 16 Dec 2022

  Annals of Urologic Oncology, Volume 5 (2022), Issue 2

  Pages: 75-80   PDF(886KB)   Views：857Downloads：4

• Recent Advances in Advance Prostate Cancer

  Nishant Lohia

  Prostate cancer being the second most frequent and fifth leading cause of mortality has led to conduct of many new clinical trials and development of newer therapeutic agents. In the last decade with better understanding of biology of disease there is dramatic improvement and sea change in survival outcomes in advanced prostate cancer with advent of chemotherapy, targeted therapy immunotherapy bes...

  REVIEW | Published: 30 Dec 2022

  Annals of Urologic Oncology, Volume 5 (2022), Issue 2

  Pages: 81-88   PDF(525KB)   Views：790Downloads：11

• Long Non-coding RNA INE1 Induced Autophagy Promotes Sensitivity of Prostate Cancer Cells to Cisplatin

  Hezhen Chu, Kongdong Li ... Jun Ma

  Prostate cancer is most prevalent malignancy of males in the world. In recent years, long non-coding RNAs (lncRNAs) were identified, and their functions are associated with prostate cancer initiation and progression. However, their molecular mechanisms still need to be elucidated before the clinical utility. In the present study, we identified the correlation of lncRNA inactivation escape 1 (INE1)...

  RESEARCH | Published: 29 Nov 2022

  Annals of Urologic Oncology, Volume 5 (2022), Issue 2

  Pages: 89-100   PDF(2470KB)   Views：709Downloads：4